Free Shipping for orders over $49 within the U.S.

Clinical Trials: Ginseng

June 08, 2020

CLINICAL TRIALS from PubMed.gov 

 

EVIDENCE FOR EFFICACY (HUMAN DATA)

A review of 20 randomized controlled studies (n=1891) concluded that Panax notoginseng saponins injection may exert multiple protective mechanisms against intracranial/intracerebral hemorrhage-induced brain damage. Xu 2015

In a 16-week randomized study (n=52), Panax notoginseng saponins combined with autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells reduced ulcer area and severity of rest pain in patients with unreconstructable critical limb ischemia. Wang 2014

A systematic review of 17 randomized clinical trials (17 papers and 1747 participants) concluded oral Panax notoginseng could relieve angina pectoris related symptoms; however, more rigorous trials with high quality are needed to provide a higher level of evidence. Shang 2013

In a 6-week, double-blind, randomized, placebo-controlled study (n=57), Panax notoginseng in formulation with two other herbs was found to be safe, tolerable and effective for symptomatic improvement of pain and physical function of knee osteoarthritis in Korean patients. Park 2009

A review of 8 randomized controlled trials (n=660) concluded Panax notoginseng appears to be beneficial and safe for acute ischemic stroke but the small sample size and inferior quality of studies prevented a definite conclusion with more well-designed trials needed. Chen 2008

In a randomized study (n=84), Panax notoginseng saponins provided a protective effect against rheumatoid arthritis, regulating disordered immunity and improving the effect of anti-inflammatory and analgesia drugs such as clofenac sodium, Leflunomide, and prednisone. [Article in Chinese] Zhang 2007

In a randomized controlled study, daily administration of Panax notoginseng for 30 days was shown to improve endurance time to exhaustion, as well as to lower mean blood pressure and Vo2 during physical endurance exercise, in untrained adults aged 20-35 years. Liang 2005

In a randomized double-blind study (n=120), Panax notoginseng was shown to decrease platelet superficial activation, inhibiting platelet adhesion and aggregation, preventing thrombosis, improving microcirculation, in patients with blood hyperviscosity syndrome. [Article in Chinese] Wang 2004